Rocket Lab's Neutron Timeline Slips to 2027 as Composite Flaw Forces a Reckoning on Execution
Published on 11/12/2026 at 10:31 | Editorial boerse-global.de
Rocket Lab investors got a reminder this week that a bulging order book counts for little until the hardware flies. The company disclosed the discovery of voids in a composite-material tank dome destined for the first stage of its Neutron rocket, pushing the maiden launch to 2027. The stock slipped 2.7% in premarket trading on the news.
The defect sits at the heart of the transition Rocket Lab must now prove it can make — from a business that wins contracts to one that delivers them profitably. Start agreements stretch years into the future; shareholders, meanwhile, grade earnings every quarter. That tension has become the central question hanging over the equity.
Two Banks, Two Verdicts on Neutron Risk
The uncertainty surrounding the Neutron schedule prompted Piper Sandler to trim its price target on Tuesday, cutting the figure from $83 to $58 while reaffirming a neutral rating, according to media reports. The brokerage also pointed to lower valuation multiples across the space sector as a factor behind the move.
Morgan Stanley took a milder view a day earlier, lowering its target from $105 to $103 but keeping its overweight rating, media reports indicated. The gap between the two calls — one slashing the target by roughly 30%, the other shaving less than 2% — captures how differently the Street is weighing the Neutron delay against Rocket Lab's commercial momentum.
Record Revenue, but Losses Weigh
The quarterly report itself, released Monday, offered ammunition for both camps. Rocket Lab posted record revenue of $268 million for the third quarter of 2026, up 73% year over year. The GAAP loss came in at $0.12 per share.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Coverage of the results flagged both the pushed-back Neutron debut and a wider-than-expected adjusted loss as drags on the shares. On the plus side, the revenue outlook for the fourth quarter landed ahead of forecasts, with Rocket Lab guiding to $270 million to $290 million for the period.
Neutron Pricing Climbs as Backlog Builds
Alongside the numbers, Rocket Lab announced eight Neutron launch missions for five satellite-constellation operators, agreements valued at more than $515 million. Several of those launches were contracted at a base price of $70 million, up from $55 million previously for multiple missions. The launch program now spans 16 missions in total.
Higher agreed prices speak to Rocket Lab's negotiating leverage — provided the missions are executed at economically viable terms. That makes pricing the more telling yardstick than the raw count of new bookings: the quality of the growth depends on what the contracts yield in operations.
The order book, as reported Monday, reached $3.57 billion. Backlog and revenue guidance offer investors different kinds of orientation — one describes contractually committed business, the other the expectation for near-term development. Together they reinforce the growth story, so long as Rocket Lab works through the orders accordingly.
The Test Shifts From Winning to Delivering
What matters now is less the next headline booking than the link between demand, pricing and losses. Rocket Lab holds a strong commercial foundation; the economic quality of that foundation still has to show up in the running business. The valuation yardstick is shifting from the ability to capture demand to the ability to serve it at a profit.
The growing contract base argues in the company's favor. Whether rising revenue and higher launch prices eventually lift earnings is the question on which the stock should be judged.
Ad
Rocket Lab Stock: New Analysis - 12 November
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
